* supervised student​
† Equal contribution
​
2025​
​
Imaging the activity of efflux transporters at the blood-brain barrier in neurological diseases: radiotracer selection criteria
Tournier N, Langer O
J Nucl Med, Accepted
​
Synaptic Vesicle 2A (SV2A) Positron Emission Tomography (PET) Imaging as a Marker of Therapeutic Response in a Mouse Model of Depression
Corvo C, Mendez-David I, Goutal S, Saba W, Bottlaender M, Caillé F, Hen R, Colle R, Corruble E, Tournier N, Leroy C, David DJ
ACS Pharm Transl Sci, Accepted
​
Decreased opioid receptor availability and impaired neurometabolic coupling as signatures of morphine tolerance in male rats: A positron emission tomography study.
Soyer A, Leterrier S, Goutal S, Corvo C, Saba W, Caillé F, Bo GD, Winkeler A, Thibault K, Leroy C, Tournier N.
Biomed Pharmacother. 2025 Jan 16;183:117848
​​
​TSPO-PET in pre-surgical evaluations: Correlation of neuroinflammation and SEEG epileptogenicity mapping in drug-resistant focal epilepsy.
Kilmer J, Rodrigo S, Petrescu AM, Aghakhani N, Herbrecht A, Leroy C, Tournier N, Bottlaender M, Taussig D, Bouilleret V.
Epilepsia 2025 Feb;66(2):430-443. doi: 10.1111/epi.18182.
Brain glucose metabolism as a neuronal substrate of the abnormal behavioral response to stress in the mdx mouse, a model of Duchenne muscular dystrophy
Goutal S†; Lancien M†; Rivier F; Tournier N, Vaillend C.
Neurobiol Dis. Jan;204:106771. doi: 10.1016/j.nbd.2024.106771.
​
2024​
​
​Successful repositioning of mertansine for improved chemotherapy by combining a polymer prodrug approach and PET imaging
Martin-Aubert S., Avrillon K, Tournier N, Bordat A, Tran V-L, Kereselidze D, Tsapis N, Nicolas J, Boissenot T, Truillet C
J Control Release, 2024 Dec 30;378:803-813. doi: 10.1016/j.jconrel.2024.12.050.
​
[11C]Metoclopramide PET can detect a seizure-induced up-regulation of cerebral P- glycoprotein in epilepsy patients
Biali ME, Breuil L, Jackwerth M, Mairinger S, Weber M, Wölfl-Duchek M, Bamminger K, Rausch I, Nics L, Hacker M, Rodrigo S, Bouilleret V, Zeitlinger M, Pataraia E, Tournier N†, Bauer M†, Langer O†.
Fluids Barriers CNS. 2024 Oct 28;21(1):87. doi: 10.1186/s12987-024-00588-8.
Impaired brain glucose metabolism as a biomarker for evaluation of dodecyl creatine ester in creatine transporter deficiency: insights from patient brain-derived organoids and in vivo [18F]FDG PET imaging in a mouse model
Disdier C; Soyer A*; Broca-Brisson L; Goutal S; Guyot A-C; Ziani N*; Breuil L; Winkeler A; Hugon G; Joudinaud T; Bénech H; Armengaud J; Skelton MR; Harati R; Hamoudi RA; Tournier N†; Mabondzo A†
Neurobiol Dis. 2024 Nov;202:106720. doi: 10.1016/j.nbd.2024.106720.
​
Brain delivery enabled by transient blood-brain barrier disruption induced by regadenoson monitored using in vivo PET imaging
Hosten B, Goutal S, Leterrier S, Corvo C, Breuil L, Barret O, Specklin S, Truillet C, Tournier N.
Expert Opin Drug Deliv. 2024 May;21(5):797-807. doi: 10.1080/17425247.2024.2369765
​​
Brain glucose metabolism as a readout of the CNS impact of cigarette smoke exposure, withdrawal, and the effects of NFL-101, as an immune-based drug candidate for smoking cessation therapy
Goutal S, Tran T, Leroy C, Benhamouda N, Leterrier S, Saba W Lafont B, Tartour E, Roelens M, Tournier N.
ACS Chem Neurosci. 2024 Jul 3;15(13):2520-2531. doi: 10.1021/acschemneuro.4c00204.
​
St. John's wort extract with a high hyperforin content does not induce P-glycoprotein activity at the human blood-brain barrier.
El Biali M, Wölfl-Duchek M, Jackwerth M, Mairinger S, Weber M, Bamminger K, Poschner S, Rausch I, Schindler N, Lozano IH, Jäger W, Nics L, Tournier N, Hacker M, Zeitlinger M, Bauer M, Langer O.
Clin Transl Sci. 2024 May;17(5):e13804. doi: 10.1111/cts.13804.
​
[18F]2-fluoro-2-deoxy-sorbitol ([18F]FDS) PET imaging repurposed for quantitative estimation of blood-brain barrier permeability in a rat model of Alzheimer’s disease
Soyer A*, Goutal S, Leterrier S, Marie S, Larrat B, Selingue E, Winkeler A, Sarazin M, Bottlaender M, Tournier N
Ann Pharm Fr., 2024 Sep;82(5):822-829. doi: 10.1016/j.pharma.2024.04.004.
​
Non-Invasive Device-Mediated Drug Delivery to the Brain across the Blood–Brain Barrier
Tashima T, Tournier N
Pharmaceutics 2024, 16(3), 361; https://doi.org/10.3390/pharmaceutics16030361
​
Imaging quantitative changes in blood-brain barrier permeability using [18F]2-fluoro-2-deoxy-sorbitol ([18F]FDS) PET in relation to glial cell recruitment in a mouse model of endotoxemia
Leterrier S, Goutal S, Hugon G*, Goislard M, Saba W, Hosten B, Specklin S, Winkeler A, Tournier N
J Cereb Blood Flow. 2024, 2024 Mar 5:271678X241236755. doi: 10.1177/0271678X241236755.
​
Performance and Sensitivity of [99mTc]Tc-sestamibi Compared with Positron Emission Tomography Radiotracers to Measure P-glycoprotein Function in the Kidneys and Liver
Hernández-Lozano I, Leterrier S, Mairinger S, Stanek J, Zacher AS, Breyer L, Hacker M, Zeitlinger M, Pahnke J, Tournier N, Wanek T, Langer O.
Mol Pharm. 2024;21(2):932-943. doi: 10.1021/acs.molpharmaceut.3c01036.
​
[11C]Metoclopramide is a sensitive radiotracer to measure moderate decreases in P-glycoprotein function at the blood-brain barrier
Mairinger S, Leterrier S, Filip T, Löbsch M, Pahnke J, Hernandès-Lozano I, Stanek J, Tournier N, Zeitlinger M, Hacker M, Langer O, Wanek T
J Cereb Blood Flow. 2024;44(1):142-152. doi: 10.1177/0271678X231202336
​
Brain PET imaging using 11C-flumazenil and 11C-buprenorphine does not support the hypothesis of a mutual interaction between buprenorphine and benzodiazepines at the neuroreceptor level
Auvity S†, Vodovar D†, Goutal S, Cisternino S, Chevillard L, Soyer A, Bottlaender M, Caillé F, Mégarbane B, Tournier N
J Cereb Blood Flow Metab, 2024;44(3):449-458. doi: 10.1177/0271678X231221040
2023
​
Successful Prediction of Human Hepatic Concentrations of Transported Drugs Using the Proteomics-Informed Relative Expression Factor Approach
Yin M, Balhara A, Marie S, Tournier N, Gáborik Z, Unadkat J
Clin Pharm Ther, 2024;115(3):595-605. doi: 10.1002/cpt.3123
​
Efficient PD-L1 imaging of murine glioblastoma with FUS-aided immunoPET by leveraging FcRn-antibody interaction.
Chevaleyre C, Novell A, Tournier N, Dauba A, Dubois S, Kereselidze D, Selingue E, Jego B, Maillère B, Larrat B, Nozach H, Truillet C.
Theranostics. 2023 Oct 16;13(15):5584-5596. doi: 10.7150/thno.87168. eCollection 2023.
​
Dissimilar Effect of P-glycoprotein and Breast Cancer Resistance Protein Inhibition on the Distribution of Erlotinib to the Retina and Brain in Humans and Mice
El Biali M, Auvity S, Cisternino S Smirnova M, Hacker M, Zeitlinger M, Mairinger S, Tournier N, Bauer M, Langer O
Mol Pharm. 2023 Nov 6;20(11):5877-5887. doi: 10.1021/acs.molpharmaceut.3c00715.
​
Parametric imaging of P-glycoprotein function at the blood-brain barrier using kE,brain-maps generated from [11C]metoclopramide PET data in rats, nonhuman primates and humans
Breuil L*, Elbiali M, Vodovar D, Marie S, Auvity S, Bauer M, Goutal S, Rodrigo S, Langer O, Tournier N.
Mol Imaging Biol. 2023;25(6):1135-1141. doi: 10.1007/s11307-023-01864-z
​
[18F]DPA-714 PET Imaging in the Presurgical Evaluation of Patients With Drug-Resistant Focal Epilepsy.
Cheval M, Rodrigo S, Taussig D, Caillé F, Petrescu AM, Bottlaender M, Tournier N, Besson FL, Leroy C, Bouilleret V.
Neurology. 2023 Nov 7;101(19):e1893-e1904. doi: 10.1212/WNL.0000000000207811.
​
Imaging the impact of blood-brain barrier disruption induced by focused ultrasound on P-glycoprotein function.
Goutal S, Novell A, Leterrier S, Breuil L, Selingue E, Gerstenmayer M, Marie S, Saubaméa B, Caillé F, Langer O, Truillet C, Larrat B, Tournier N.
J Control Release. 2023 Aug 14;361:483-492
Carbon Dioxide Radical Anion by Photoinduced Equilibration between Formate Salts and [11C, 13C, 14C]CO2: Application to Carbon Isotope Radiolabeling.
Malandain A, Molins M, Hauwelle A, Talbot A, Loreau O, D'Anfray T, Goutal S, Tournier N, Taran F, Caillé F, Audisio D.
J Am Chem Soc. 2023 Aug 2;145(30):16760-16770. doi: 10.1021/jacs.3c04679.
​
A pharmacological imaging challenge based on 11C-buprenorphine PET-MRI to explore the response to opioids in humans
Leroy C, Goutal S, Breuil L*, Gervais P, Cherkaoui H, Ciuciu P, Auvity S*, Vodovar D*, Comtat C, Lebon V, Bottlaender M, Tournier N
Eur J Nucl Med Mol Imaging, 2023 Aug;50(10):3153-3154. doi: 10.1007/s00259-023-06253-w.
​
Validation of a Pharmacological Imaging Challenge using 11C-Buprenorphine and 18F-2-Fluoro-2-deoxy-D-Glucose Positron Emission Tomography to Study the Effects of Buprenorphine to the Rat Brain
Soyer A*, Leterrier S, Breuil L, Goislard M, Leroy C, Saba W, Thibault K, Dal Bo G, Bottlaender M, Caillé F, Goutal S, Tournier N
Front Neurosci, 2023 May 10;17:1181786. doi: 10.3389/fnins.2023.1181786.
​
Breuil L, Marie S, Tournier N
J Pharm Sci. 2023 Apr 4:S0022-3549(23)00143-0. doi: 10.1016/j.xphs.2023.03.023.
Influence of P-glycoprotein on pulmonary disposition of the model substrate [11C]metoclopramide assessed by PET imaging in rats.
Mairinger S, Hernández-Lozano I, Filip T, Löbsch M, Stanek J, Zeitlinger M, Hacker M, Tournier N, Wanek T, Ehrhardt C, Langer O.
Eur J Pharm Sci. 2023 Apr 1;183:106404. doi: 10.1016/j.ejps.2023.106404.
​
​
2022
​
Breuil L, Ziani N, Leterrier S, Hugon G, Caillé F, Bouilleret V, Truillet C, Goislard M, El Biali M, Bauer M, Langer O, Goutal S, Tournier N.
Pharmaceutics. 2022 Nov 30;14(12):2650. doi: 10.3390/pharmaceutics14122650.
Isotopic radiolabeling of crizotinib with fluorine-18 for in vivo PET imaging
Sardana M, Breuil L*, Goutal S, Goislard M, Kondrashov M, Marchal E, Besson F, Dugave D, Wrigley G, Jonson AC, Kuhnast B, Schou M,
Tournier N, Elmore CS, Caillé F
Pharmaceuticals (Basel). 2022 Dec 15;15(12):1568. doi: 10.3390/ph15121568.
​
Regulation of P-glycoprotein and breast cancer resistance protein expression induced by focused ultrasound-mediated blood-brain barrier disruption: a pilot study
Conti A, Geffroy F, Arytto H, Kamimura S, Novell A, Tournier N, Mériaux S, Larrat B
Int J Mol Sci. 2022 Dec 7;23(24):15488. doi: 10.3390/ijms232415488.
​
Impact of cytochrome induction or inhibition on the plasma and brain kinetics of [11C]metoclopramide, a PET probe for P-glycoprotein function at the blood-brain barrier
Breuil L*, Ziani N, Leterrier S, Hugon G, Caillé F, Bouilleret V, Truillet C, Goislard M, El Biali M, Bauer M, Langer O, Goutal S, Tournier N
Pharmaceutics. 2022 Nov 30;14(12):2650. doi: 10.3390/pharmaceutics14122650.
[11C]glyburide PET imaging for quantitative determination of the importance of Organic Anion-Transporting Polypeptide transporter function in the human liver and whole-body
Marie S, Breuil L*, Chalampalakis Z, Becquemont L, Verstuyft C, Lecoq Anne-Lise, Caillé F, Gervais P, Lebon V, Comtat C, Bottlaender M, Tournier N
Biomed Pharmacother, 2022, 156, 113994
Chevaleyre C, Kereselidze D, Caillé C, Tournier N, Olaciregui NG, Winkeler A, Declèves X, Jego B, Cisternino S, Auvity S, Truillet C
Int J Mol Sci, 2022 Oct 18;23(20):12476. doi: 10.3390/ijms232012476.
​
Investigation of the mechanisms of tramadol-induced seizures in overdose in the rat
Lagard C†, Vodovar D†*, Chevillard L, Callebert J, Caillé F, Pottier G, Liang H, Risède P, Tournier N, Mégarbane B
Pharmaceuticals, 2022 Oct 12;15(10):1254. doi: 10.3390/ph15101254.
Abnormal expression of synaptic and extrasynaptic GABAA receptor subunits in the dystrophin-deficient mdx mouse
Zarrouki F, Goutal S, Vacca O, Garcia L, Tournier N, Goyenvalle A, Vaillend C
Int J Mol Sci, 2022 Oct 20;23(20):12617. doi: 10.3390/ijms232012617.
Breuil L*, Goutal S, Marie S, Del Vecchio A, Audisio D, Soyer A*, Goislard M, Saba W, Tournier N†, Caillé F†.
Pharmaceutics. 2022 Aug 9;14(8):1658. doi: 10.3390/pharmaceutics14081658.PMID: 36015284
​
Isotopic Radiolabeling of the Antiretroviral Drug [18F]Dolutegravir for Pharmacokinetic PET Imaging
Tisseraud M, Goutal S, Bonasera T, Goislard M, Desjardins D, Le Grand R,, Parry C.M, Tournier N, Kuhnast B, Caillé F
Pharmaceuticals, 2022, 15(5), 587; https://doi.org/10.3390/ph15050587
​
Pharmacokinetic imaging using 99mTc-mebrofenin to untangle the pattern of hepatocyte transporter disruptions
induced by endotoxemia in rats
Marie S, Hernández-Lozano I, Le Vée M, Breuil L, Saba W, Goislard M, Goutal S, Truillet C, Langer O, Fardel O, Tournier N
Pharmaceuticals, 2022 Mar 24;15(4):392. doi: 10.3390/ph15040392.
​
Impact of Donepezil on Brain Glucose Metabolism Assessed Using [18F]2-Fluoro-2-deoxy-D-Glucose Positron Emission Tomography Imaging in a Mouse Model of Alzheimer’s Disease Induced by Intracerebroventricular Injection of Amyloid-Beta Peptide
Hugon G*, Goutal S, Sarazin M, Bottlaender M, Caillé F, Droguerre M, Charvériat M, Winkeler A, Tournier N
Front Neurosci. 2022 Feb 25;16:835577. doi: 10.3389/fnins.2022.835577.
​
Caillé F, Saba W, Goutal S, Breuil L*, Kuhnast B, Tournier N.
J Labelled Comp Radiopharm. 2022 Feb;65(2):28-35. doi: 10.1002/jlcr.3957.
​
Mechanism of respiratory depression induced by the combination of buprenorphine and diazepam in rats
Vodovar D*, Chevillard L, Caillé F, Risède P, Pottier G, Auvity S*, Mégarbane B†, Tournier N†
Br J Anaesth. 2022 Mar;128(3):584-595. doi: 10.1016/j.bja.2021.10.029
​
Breuil L*, Marie S*, Goutal S, Auvity S, Truillet C, Saba W, Langer O, Caillé F, Tournier N.
J Cereb Blood Flow Metab. 2022 Jan;42(1):175-185. doi: 10.1177/0271678X211045444.
​
2021
​
[18F]2-fluoro-2-deoxy-sorbitol PET imaging for quantitative monitoring of enhanced blood-brain barrier permeability induced by focused ultrasound
Hugon G, Goutal S, Dauba A, Breuil L, Larrat B, Winkeler A, Novell A, Tournier N
Pharmaceutics. 2021, 13, 1752. https://doi.org/10.3390/pharmaceutics13111752
​
Imaging-Based Characterization of a Slco2b1(-/-) Mouse Model Using [11C]Erlotinib and [99mTc]Mebrofenin as Probe Substrates
Marie S*, Hernández-Lozano I, Breuil L*, Truillet C, Hu S, Sparreboom A, Tournier N, Langer O
Pharmaceutics, 2021 Jun 21;13(6):918. doi: 10.3390/pharmaceutics13060918.
​
Quantitative tissue pharmacokinetics and EPR effect of AGuIX® nanoparticles: a multimodal imaging study in an orthotopic glioblastoma rat model and healthy macaque
Tran V-L, Lux F, Tournier N, Jego B, Maître X, Anisorac M, ComtatC, Jan S, Selmeczi K, Evans M-J, Tillement O, Kuhnast B, Truillet C
Advanced NanoBiomed Research, 2021 Aug;10(16):e2100656. doi: 10.1002/adhm.202100656.
​
ABCB1 and ABCG2 together limit the distribution of ABCB1/ABCG2 substrates to the human retina and the ABCG2 single nucleotide polymorphism Q141K (c.421C>A) may lead to increased drug exposure
El Biali M, Karch R, Philippe C, Haslacher H, Tournier N, Hacker M, Zeitlinger M, Schmidl D, Langer O, Bauer M
Frontiers in Pharmacology, 2021 Jun 16;12:698966. doi: 10.3389/fphar.2021.698966. eCollection 2021.
​
Repurposing 99mTc-mebrofenin as a probe for molecular imaging of hepatocyte transporters
Marie S, Hernández-Lozano I, Langer O, Tournier N
J Nucl Med. 2021 Aug 1;62(8):1043-1047. doi: 10.2967/jnumed.120.261321.
​
Pharmacokinetic neuroimaging to study the dose-related brain kinetics and target engagement of buprenorphine in vivo
Auvity S, Goutal S, Caillé F, Vodovar D, Pruvost A, Wimberley C, Leroy C, Tonietto M, Bottlaender M, Tournier N
Neuropsychopharmacol. 2021 May;46(6):1220-1228. doi: 10.1038/s41386-021-00976-w.
​
Human Biodistribution and Radiation Dosimetry of the P-Glycoprotein Radiotracer [11C]Metoclopramide.
Bauer M, Barna S, Blaickner M, Prosenz K, Bamminger K, Pichler V, Tournier N, Hacker M, Zeitlinger M, Karanikas G, Langer O.
Mol Imaging Biol. 2021 Apr;23(2):180-185. doi: 10.1007/s11307-021-01582-4.
​
Influence of cation transporters (OCTs and MATEs) on the renal and hepatobiliary disposition of [11C]metoclopramide in mice
Hernández-Lozano I, Mairinger S, Sauberer M, Stanek J, Filip T, Wanek T, Ciarimboli G, Tournier N, Langer O
Pharm Res. Jan;38(1):127-140. doi: 10.1007/s11095-021-03002-2
​
Impaired clearance from the brain increases the brain exposure to metoclopramide in elderly subjects
Bauer M, Bamminger K, Pichler V, Weber M, Binder S, Maier-Salamon A, Tahir A, Jaeger W, Haslacher H, Tournier N, Hacker M, Zeitlinger M, Langer O
Clin Pharm Ther, 2021 Mar;109(3):754-761. doi: 10.1002/cpt.2052.
​
Complete inhibition of ABCB1 and ABCG2 at the blood-brain barrier by co-infusion of erlotinib and tariquidar to improve brain delivery of the model ABCB1/ABCG2 substrate [11C]erlotinib
Tournier N, Goutal S, Mairinger S, Hernández Lozano I, Filip T, Sauberer M, Caillé F, Breuil L*, Stanek J, Freeman AF, Novarino G, Truillet C, Wanek T, Langer O
J Cereb Blood Flow Metab, 2021 Jul;41(7):1634-1646. doi: 10.1177/0271678X20965500.
​
2020
Ventilatory depression following oral buprenorphine exposure: insight into the involved mechanisms
Vodovar D*, Tournier N, Mégarbane B
Clin Tox, 2020 Nov 2:1-2. doi: 10.1080/15563650.2020.1837858.
​
Challenges and perspectives of the hybridization of PET with functional MRI or ultrasound for neuroimaging
Tournier N, Comtat C, Lebon V, Gennisson J-L.
Neuroscience, 2020 Oct 20:S0306-4522(20)30666-7. doi: 10.1016/j.neuroscience.2020.10.015.
​
Comparative test-retest variability of outcome parameters derived from brain [18F]FDG PET studies in non-human primates
Goutal S, Tournier N, Guillermier M, Van-Camp N, Barret O, Gaudin M, Bottlaender M, Hantraye P, Lavisse S.
Plos One, 2020 Oct 5;15(10):e0240228. doi: 10.1371/journal.pone.0240228. eCollection 2020.
​
Nalmefene alleviates the neuroimmune response to repeated binge-like ethanol exposure: a TSPO PET imaging study in adolescent rats
Tournier N, Pottier G, Caillé F, Coulon C, Goislard M, Jégo B, Negroni J, Leroy C, Saba W
Addition Biology. 2020 Sep 7:e12962. doi: 10.1111/adb.12962.
​
Tran VL, Novell A, Tournier N, Gerstenmayer M, Schweitzer-Chaput A, Mateos C, Jego B, Bouleau A, Nozach H, Winkeler A, Kuhnast B, Larrat B, Truillet C.
J Control Release. 2020 Aug 26:S0168-3659(20)30488-0. doi: 10.1016/j.jconrel.2020.08.047.
​
An Original Radio-biomimetic Approach to Synthesize Radiometabolites for PET Imaging.
Auvity S, Breuil L*, Goislard M, Bottlaender M, Kuhnast B, Tournier N, Caillé F
Nucl Med Biol, 2020 Aug 23;90-91:10-14. doi: 10.1016/j.nucmedbio.2020.08.001.
​
Validation of Pharmacological Protocols for Targeted Inhibition of Canalicular MRP2 Activity in Hepatocytes Using [99mTc]mebrofenin Imaging in Rats.
Marie S*, Hernández-Lozano I, Breuil L*, Saba W, Novell A, Gennisson JL, Langer O, Truillet C, Tournier N.
Pharmaceutics. 2020 May 27;12(6):E486. doi: 10.3390/pharmaceutics12060486.
​
PET imaging to study the functional impact of P-glycoprotein for neuropharmacokinetics.
Marie S*, Tournier N
Therapies. 2020 Feb 22:S0040-5957(20)30043-3. doi: 10.1016/j.therap.2020.02.018.
​
Automated two-step manufacturing of [11C]glyburide radiopharmaceutical for PET imaging in humans.
Caillé F, Gervais P, Auvity S, Coulon C, Marie S*, Tournier N, Kuhnast B
Nucl Med Biol. 2020 Jan 7;84-85:20-27. doi: 10.1016/j.nucmedbio.2019.12.008.
​
Imaging P-glycoprotein Induction at the Blood-Brain Barrier of a Beta-Amyloidosis Mouse Model with 11C-Metoclopramide PET.
Zoufal V, Mairinger S, Brackhan M, Krohn M, Filip T, Sauberer M, Stanek J, Wanek T, Tournier N, Bauer M, Pahnke J, Langer O
J Nucl Med. 2020 Jul;61(7):1050-1057. doi: 10.2967/jnumed.119.237198.
​
​
2019
Proof-of-Concept Study of Drug Brain Permeability Between in Vivo Human Brain and an in Vitro iPSCs-Human Blood-Brain Barrier Model
Le Roux G, Jarray R, Guyot AC, Pavoni S, Costa N, Théodoro F, Nassor F, Pruvost A, Tournier N, Kiyan Y, Langer O, Yates F, Deslys JP Mabondzo A
Sci Rep. 2019 Nov 5;9(1):16310. doi: 10.1038/s41598-019-52213-6.
​
Repurposing radiotracers for myelin imaging: a study comparing 18F-florbetaben, 18F-florbetapir, 18F-flutemetamol,11C-MeDAS, and 11C-PiB.
Auvity S, Tonietto M, Caillé F, Bodini B, Bottlaender M, Tournier N, Kuhnast B, Stankoff B.
Eur J Nucl Med Mol Imaging. 2020 Feb;47(2):490-501. doi: 10.1007/s00259-019-04516-z. Epub 2019 Nov 4.
​
11C-glyburide PET imaging unveils the negligible brain penetration of glyburide in human
Marie S*, Comtat C, Caillé F, Becquemont L, Bottlaender M, Tournier N
Neurology, 2019 Apr 23;92(17):813-814. doi: 10.1212/WNL.0000000000007378.
​
Imaging P-glycoprotein function at the blood-brain barrier as a determinant of the variability in response to CNS drugs
Bauer M, Tournier N, Langer O
Clin Pharm Ther, 2019 May;105(5):1061-1064. doi: 10.1002/cpt.1402.
​
Traxl A, Mairinger S, Filip T, Sauberer M, Stanek J, Poschner S, Jäger W, Zoufal V, Novarino G, Tournier N, Bauer M, Wanek T, Langer O.
Mol Pharm. 2019 Mar 4;16(3):1282-1293. doi: 10.1021/acs.molpharmaceut.8b01217.
​
Impact of P-glycoprotein Function on the Brain Kinetics of the Weak Substrate 11C-Metoclopramide Assessed with PET Imaging in Humans
Tournier N†, Bauer M†, Pichler V, Nics L, Klebermass E-M, Bamminger K, Matzneller P, Weber M, Karch R, Caille F, Auvity S, Marie S, Jaeger W, Wadsak W, Hacker M, Zeitlinger M, Langer O.
J Nucl Med, 2019 Jul;60(7):985-991. doi: 10.2967/jnumed.118.219972.
​
The American opioid overdose crisis: A threat for France?
Vodovar D, Langrand J, Tournier N, Mégarbane B.
Rev Med Interne. 2019 Jun;40(6):389-394. doi: 10.1016/j.revmed.2018.10.389.
​
Impact of acute alcohol exposure on P-glycoprotein function at the blood-brain barrier assessed using 11C-metoclopramide PET imaging
Auvity S, Tournier N
Clin Pharm Ther, 2019 Apr;105(4):812-813. doi: 10.1002/cpt.1266
​
A Proof-of-Concept Study to Inhibit ABCG2- and ABCB1-Mediated Efflux Transport at the Human Blood-Brain Barrier
Bauer M, Karch R, Wulkersdorfer B, Philippe C, Nics L, Klebermass E-M, Weber M, Poschner S,Haslacher H, Jäger W, Tournier N, Wadsak W, Hacker M, Zeitlinger M, Langer O.
J Nucl Med, 2019 Apr;60(4):486-491. doi: 10.2967/jnumed.118.216432.
​
2018
Physical blood-brain barrier disruption induced by focused ultrasound does not overcome the transporter-mediated efflux of erlotinib.
Goutal S, Gerstenmayer M, Auvity S, Caillé F, Mériaux S, Buvat I, Larrat B†, Tournier N†.
J Control Release. 2018 Dec 28;292:210-220. doi: 10.1016/j.jconrel.2018.11.009.
​
Effect of rifampicin on the distribution of [11C]erlotinib to the liver, a translational PET study in humans and in mice
Bauer M, Traxl A, Matsuda A, Karch R, Philippe C, Nics L, Klebermass EM, Wulkersdorfer B, Weber M, Poschner S, Tournier N, Jäger W, Wadsak W, Hacker M, Wanek T, Zeitlinger M, Langer O.
Mol Pharm, 2018 Oct 1;15(10):4589-4598. doi: 10.1021/acs.molpharmaceut.8b00588.I
​
P-glycoprotein (ABCB1) inhibits the influx and increases the efflux of 11C-metoclopramide across the blood-brain barrier: a PET study on non-human primates
Auvity S*, Caillé F, Marie S*, Wimberley C, Bauer M, Langer O, Buvat I, Goutal S, Tournier N
J Nucl Med, 2018 Oct;59(10):1609-1615. doi: 10.2967/jnumed.118.210104.
​
Impact of rifampicin-inhibitable transport on the liver distribution and tissue kinetics of erlotinib assessed with PET imaging in rats.
Amor D*, Goutal S, Marie S*, Caillé F, Bauer M, Langer O, Auvity S, Tournier N
EJNMMI Res, 2018 Aug 16;8(1):81. doi: 10.1186/s13550-018-0434-0.
​
Positron Emission Tomography Imaging Reveals an Importance of Saturable Liver Uptake Transport for the Pharmacokinetics of Metoclopramide
Caillé F, Goutal S, Marie S*, Auvity S*, Cisternino S, Kuhnast B, Pottier G, Tournier N
Contrast Media Mol Imaging, 2018:7310146. doi: 10.1155/2018/7310146. eCollection 2018.
​
Imaging techniques to study drug transporter function in vivo
Tournier N, Stieger B, Langer O
Pharmacol Ther, 2018 Sep;189:104-122. doi: 10.1016/j.pharmthera.2018.04.006. Pdf
​
Cortico-amygdala-striatal activation by modafinil/flecainide combination
Vodovar D*†, Duchêne A†, Wimberley C, Leroy C, Pottier G, Dauvilliers Y, Giaume C, Lin J-S, Mouthon F, Tournier N, Charvériat M
Int J Neuropsychopharmacol. 2018 Jul 1;21(7):687-696. doi: 10.1093/ijnp/pyy027.
​
​Intravenous infusion for the controlled exposure to the dual ABCB1 and ABCG2 inhibitor elacridar in nonhuman primates
Goutal S*, Langer O, Auvity S*, Andrieux K, Coulon C, Caillé F, Gervais P, Cisternino S, Declèves X, Tournier N
Drug Deliv Transl Res. 2018 Jun;8(3):536-542. doi: 10.1007/s13346-017-0472-6.
​
Imaging the neuroimmune response to alcohol exposure in adolescent baboons: a TSPO PET study using 18F-DPA-714
Saba W, Goutal S, Auvity S*, Kuhnast B, Coulon C, Kouyoumdjian V*, Buvat I, Leroy C, Tournier N.
Addict Biol. 2018 23:1000–1009. https://doi.org/10.1111/adb.12548.
​
2017
​
​​
Imaging Probes and Modalities for the Study of Solute Carrier O (SLCO)-Transport Function In Vivo. Marie S*, Cisternino S, Buvat I, Declèves X, Tournier N.
J Pharm Sci. 2017 Sep;106(9):2335-2344.
​
Acute Morphine Exposure Increases the Brain Distribution of [18F]DPA-714, a PET Biomarker of Glial Activation in Nonhuman Primates.
Auvity S*, Saba W, Goutal S, Leroy C, Buvat I, Cayla J, Caillé F, Bottlaender M, Cisternino S, Tournier N.
Int J Neuropsychopharmacol. 2017;20(1):67-71 , https://doi.org/10.1093/ijnp/pyw077
​​
Assessment of P-glycoprotein Transport Activity at the Human Blood-Retinal Barrier with (R)-11C-verapamil PET.
Bauer M, Karch R, Tournier N, Cisternino S, Wadsak W, Hacker M, Marhofer P, Zeitlinger M, Langer O.
J Nucl Med. 2017;58(4):678-681
​
Strategies to inhibit ABCB1- and ABCG2-mediated efflux transport of erlotinib at the blood-brain barrier: a PET study in non-human primates.
Tournier N, Goutal S*, Auvity S*, Traxl A, Mairinger S, Wanek T, Helal OB, Buvat I, Soussan M, Caillé F, Langer O.
J Nucl Med. 2017;58:117-122
​
​Evaluation of TSPO PET imaging, a marker of glial activation, to study the neuroimmune footprints of morphine exposure and withdrawal.
Auvity S*, Goutal S, Thézé B, Chaves C, Hosten B, Kuhnast B, Saba W, Boisgard R, Buvat I, Cisternino S, Tournier N.
Drug Alcohol Depend. 2017;170:43-50. doi: 10.1016/j.drugalcdep.2016.10.037.
​
Diphenhydramine as a selective probe to study H+-antiporter function at the blood-brain barrier: Application to [11C]diphenhydramine positron emission tomography imaging.
Auvity S*, Chapy H, Goutal S, Caillé F, Hosten B, Smirnova M, Declèves X, Tournier N†, Cisternino S†.
J Cereb Blood Flow Metab. 2017;37(6):2185-2195.
2016
​
Imaging the impact of cyclosporin A and dipyridamole on P-glycoprotein (ABCB1) function at the blood-brain barrier: A [(11)C]-N-desmethyl-loperamide PET study in nonhuman primates.
Damont A, Goutal S, Auvity S*, Valette H, Kuhnast B, Saba W, Tournier N.
Eur J Pharm Sci. 2016;91:98-104
​
Simultaneous Determination of Eight β-Lactam Antibiotics, Amoxicillin, Cefazolin, Cefepime, Cefotaxime, Ceftazidime, Cloxacillin, Oxacillin, and Piperacillin, in Human Plasma by Using Ultra-High-Performance Liquid Chromatography with Ultraviolet Detection.
Legrand T, Vodovar D, Tournier N, Khoudour N, Hulin A.
Antimicrob Agents Chemother. 2016;60(8):4734-42.
​
Validation of a simple HPLC-UV method for rifampicin determination in plasma: Application to the study of rifampicin arteriovenous concentration gradient
Goutal S, Auvity S*, Legrand T, Hauquier F, Cisternino S, Chapy H, Saba W, Tournier N.
J Pharm Biomed Anal. 2016;123:173-178
​
Imaging the impact of the P-glycoprotein (ABCB1) function on the brain kinetics of metoclopramide
Pottier G, Marie S*, Goutal S, Auvity S*, Peyronneau M, Stute S, Boisgard R, Dollé F, Buvat I, Caillé F, Tournier N.
J Nucl Med. 2016;57(2):309-14
​
Blood-brain and retinal barriers show dissimilar ABC transporter impacts and concealed effect of P-glycoprotein on a novel verapamil influx carrier
Chapy H, Saubaméa B, Tournier N, Bourasset F, Declèves X, Behar-Cohen F, Scherrmann JM, Cisternino S,
Br J Pharmacol. 2016;173(3):497-510
​
Previous
​
Differential influence of propofol and isoflurane anesthesia in non-human primate on the brain kinetics and binding of [18F]DPA-714, a PET imaging marker of glial activation.
Saba W, Goutal S, Kuhnast B, Dollé F, Auvity S*, Fontyn Y, Cayla J, Peyronneau MA, Valette H, Tournier N. `
Eur J Neurosci. 2015; 42(1):1738-45
​
Influence of P-Glycoprotein Inhibition or Deficiency at the Blood-Brain Barrier on (18)F-2-Fluoro-2-Deoxy-D-glucose ((18)F-FDG) Brain Kinetics
​​ Tournier N, Saba W, Goutal S, Gervais P, Valette H, Scherrmann JM, Bottlaender M, Cisternino S.
AAPS J. 2015;17(3):652-9
​
[¹¹C]befloxatone brain kinetics is not influenced by Bcrp function at the blood-brain barrier: a PET study using Bcrp TGEM knockout rats
Hosten B*, Boisgard R, Jacob A, Goutal S, Saubaméa B, Dollé F, Scherrmann JM, Cisternino S, Tournier N.
Eur J Pharm Sci. 2013;50:520-5
​
Effects of selected OATP- and/or ABC-transporter inhibitors on the brain and whole-body distribution of glyburide
Tournier N, Saba W, Cisternino S, Peyronneau M-A, Damont A, Goutal S, Dubois A, Dolle F, Scherrmann J-M., Valette H, et al.
AAPS J. 2013; 15:1082-90
​
Gender and strain contributions to the variability of buprenorphine-related respiratory toxicity in mice
Alhaddad H, Cisternino S, Saubamea B, Schlatter J, Chiadmi F, Risède P, Smirnova M, Cochois-Guégan V, Tournier N, Baud FJ, Mégarbane B. Toxicology. 2013;305:99-108
​
Respiratory toxicity of buprenorphine results from the blockage of P-glycoprotein-mediated efflux of norbuprenorphine at the blood-brain barrier in mice
Alhaddad H, Cisternino S, Declèves X, Tournier N, Schlatter J, Chiadmi F, Risède P, Smirnova M, Besengez C, Scherrmann JM, Baud FJ, Mégarbane B. Crit Care Med. 2012;40(12):3215-23
​
Discrepancies in the P-glycoprotein-Mediated Transport of 18F-MPPF: A Pharmacokinetic Study in Mice and Non-human Primates
Tournier N, Cisternino S, Peyronneau MA, Goutal S, Dolle F, Scherrmann JM, Bottlaender M, Saba W, Valette H.
Pharm Res. 2012;29(9):2468-76​
​
Transport of selected PET radiotracers by human P glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2): an in vitro screening
Tournier N, Valette H, Peyronneau MA, Saba W, Goutal S, Kuhnast B, Dolle F, Scherrmann JM, Cisternino S, Bottlaender M.
J Nucl Med. 2011; 52(3):415-23
Received the Alavi-Mandel Award (Young investigator Award) from the Society of Nuclear Medicine and Molecular Imaging (2012)
​
​Opioid transport by ATP-binding cassette (ABC) transporters at the blood-brain barrier: implications for neuropsychopharmacology
Tournier N, Decleves X, Saubaméa B, Scherrmann JM, Cisternino S.
Curr Pharm Des. 2011;17(26):2829-42
​
Interaction of drugs of abuse and maintenance treatments with human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)
Tournier N, Chevillard L, Mégarbane B, Pirnay S, Scherrmann JM, Decleves X.
Int J neuropsychopharmacol. 2010; 13(7):905-15
​
Ibogaine labeling with 99mTc-tricarbonyl: synthesis and transport at the mouse blood-brain barrier
Tournier N, André P, Blondeel S, Rizzo-Padoin N, du Moulinet D’Hardemarre A, Declèves X, Scherrmann JM, Cisternino S.
J Pharm Sci. 2009; 98(12):4650-60
​
Changes in dipole membrane potential at the mouse blood-brain barrier enhance the transport of 99mTechnetium Sestamibi more than inhibiting Abcb1, Abcc1, or Abcg2
Cattelotte J, Tournier N, Rizzo-Padoin N, Schinkel AH, Scherrmann JM, Cisternino S.
J Neurochem. 2009; 108(3):767-75
​
Preparation and stability of voriconazole eye drop solution
Dupuis A, Tournier N, Le Moal G, Venisse N.
Antimicrob Agents Chemother. 2009; 53(2):798-9
​
Barrière hémato-encéphalique : implication des transporteurs ABC en neuropharmacologie
Dauchy S, Tournier N, Yousif S, Jacob A, Declèves X.
Réanimation. 2008;17, 664-9
​
Determination of atazanavir in human plasma using solid-phase extraction and high-performance liquid chromatography
​ Cateau E, Tournier N, Dupuis A, Le Moal G, Venisse N.
J Pharmaceut Biomed. 2005; 39(3-4):791-5
​
Books
​
« Médicaments en gériatrie » Tournier N, Legrand T, Richard D. Edition Lamarre 2006 (126p.)
« Médicaments en psychiatrie » Richard D, Senon JL, Tournier N. Edition Lamarre 2006 (135p.)
« Médicaments anticancéreux: l'essentiel » Richard D, Roustit M, Tournier N. Groupe Liaison 2003 (182p.)
​
​
Medical & pharmaceutical press articles
​
« L'imagerie au service de la Pharmacocinétique »
Tournier N, Grognet JM
L'observatoire, la lettre de l'académie nationale de pharmacie. 2017(40)
​
« La radio-immunothérapie par Zévalin » Le Moniteur Hospitalier (mai 2007)
​
« Radiopharmacie » Le Moniteur Hospitalier (juin-juillet 2006)
​
« Médication du sujet âgé : un nouveau défi pharmaceutique » Le Moniteur Hospitalier (mars 2006)
2nd award by the medical press syndicate
